Results 131 to 140 of about 5,054 (206)

Refractory verrucous psoriasis achieving clearance with guselkumab and subsequent response to excimer therapy. [PDF]

JAAD Case Rep
Moore LC, Cockerell C, Moore AY.
europepmc   +1 more source

IMPACT study: large real-world evaluation of guselkumab in psoriatic arthritis integrating clinical response and treatment persistence. [PDF]

Ther Adv Musculoskelet Dis
Paci V, Foti R, Pantano I, Carletto A, Celletti E, Miceli GF, Cangemi I, Lopalco G, Montalbano S, Chimenti MS, Picchianti Diamanti A, Massafra U, Filippucci E, Parisi A, Leccese P, Panaccione A, Puca I, Amato G, Marrone S, Di Penta M, Corrao S, Cela E, Rai A, Tirri E, Iannone F, Atzeni F, Rossini M, Ciccia F, Foti R, Moroncini G, Luchetti Gentiloni MM.   +30 more
europepmc   +1 more source

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. [PDF]

J Dermatol
Puig L, Tsai TF, Soriano ER, Bhutani T, Miller M, Kollmeier AP, Li S, Li H, Ofori S, Pawlikowski J, Adamson E, Gooderham M, Londoño Garcia A, Lebwohl M, Nash P.   +14 more
europepmc   +1 more source

New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review. [PDF]

Dermatol Ther (Heidelb)
Wang G, Youn SW, Chang CL, Saeki H.
europepmc   +1 more source

Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region. [PDF]

Clin Pract
Gemma GPA, Bernardini N, Sasso FP, Caldarola G, De Luca E, Greco ME, Lora V, Mazzotta A, Miraglia E, Orsini D, Pagnanelli G, Richetta AG, Skroza N, Dattola A.   +13 more
europepmc   +1 more source

A new association of cutaneous leishmaniasis with guselkumab in a patient with chronic psoriasis. [PDF]

Skin Health Dis
Chiang YH, Winter S, Kalavala M.
europepmc   +1 more source

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Zhang S, Lam T, Du Y, Chen X, Zhang H, Li L, Zhang G.   +6 more
europepmc   +1 more source

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Richard N, Fumery M.
europepmc   +1 more source

Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report. [PDF]

Cureus
Furuichi N, Itoi Y, Oshima K, Takeuchi Y, Uraoka T.   +4 more
europepmc   +1 more source

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Hsu CC, Huang YH, Tsai TF.
europepmc   +1 more source